

SCIENTIFIC REPORTS



OPEN

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis

Received: 16 September 2016

Accepted: 21 November 2016

Published: 04 January 2017

Zoltan Lohinai^{1,2,*}, Thomas Klikovits^{2,*}, Judit Moldvay¹, Gyula Ostoros¹, Erzsebet Raso³, Jozsef Timar^{3,4}, Katalin Fabian⁵, Ilona Kovalszky⁶, István Kenessey³, Clemens Aigner^{2,7}, Ferenc Renyi-Vamos⁸, Walter Klepetko², Balazs Dome^{1,2,8,9,†} & Balazs Hegedus^{2,4,†}

Current guidelines lack comprehensive information on the metastatic site-specific role of KRAS mutation in lung adenocarcinoma (LADC). We investigated the effect of KRAS mutation on overall survival (OS) in this setting. In our retrospective study, 500 consecutive Caucasian metastatic LADC patients with known KRAS mutational status were analyzed after excluding 32 patients with EGFR mutations. KRAS mutation incidence was 28.6%. The most frequent metastatic sites were lung (45.6%), bone (26.2%), adrenal gland (17.4%), brain (16.8%), pleura (15.6%) and liver (11%). Patients with intrapulmonary metastasis had significantly increased KRAS mutation frequency compared to those with extrapulmonary metastases (35% vs 26.5%, $p = 0.0125$). In contrast, pleural dissemination and liver involvement were associated with significantly decreased KRAS mutation incidence (vs all other metastatic sites; 17% ($p < 0.001$) and 16% ($p = 0.02$) vs 33%, respectively). Strikingly, we found a significant prognostic effect of KRAS status only in the bone metastatic subcohort (KRAS-wild-type vs KRAS-mutant; median OS 9.7 vs 3.7 months; HR, 0.49; 95% CI, 0.31 to 0.79; $p = 0.003$). Our study suggests that KRAS mutation frequency in LADC patients shows a metastatic site dependent variation and, moreover, that the presence of KRAS mutation is associated with significantly worse outcome in bone metastatic cases.

Oncogenic mutations of the Kirsten rat sarcoma viral oncogene homolog gene (KRAS) are frequently identified in lung, colorectal and pancreatic cancers¹. In lung adenocarcinoma (LADC), the mutation rate was found to be up to 30%²⁻⁵. KRAS is a proto-oncogene that is a downstream member of the epidermal growth factor receptor (EGFR) signaling pathway. KRAS and EGFR activating mutations have been described to be usually mutually exclusive⁶.

¹National Koranyi Institute of Pulmonology, Budapest, Hungary. ²Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria. ³2nd Department of Pathology, Semmelweis University, Budapest, Hungary. ⁴Molecular Oncology Research Group, Hungarian Academy of Sciences-Semmelweis University, Budapest, Hungary. ⁵Department of Pulmonology, Semmelweis University, Budapest, Hungary. ⁶1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. ⁷Department of Thoracic Surgery, Ruhrlandklinik Essen, University Hospital of University Duisburg-Essen, Essen, Germany. ⁸Department of Thoracic Surgery, National Institute of Oncology-Semmelweis University, Budapest, Hungary. ⁹Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. *These authors contributed equally to this work. †These authors jointly supervised this work. Correspondence and requests for materials should be addressed to B.D. (email: balazs.dome@meduniwien.ac.at) or B.H. (email: balazs.hegedus@meduniwien.ac.at)

While extensive data is available on the predictive and prognostic significance of KRAS mutation in colorectal carcinoma (CRC), we have ambiguous information on its prognostic role in lung cancer. In CRC, the presence of KRAS mutation is associated with increased metastatic potential and lack of treatment benefit from anti-EGFR monoclonal antibody therapy^{7,8}. CRC patients with KRAS-mutant tumors have worse overall survival (OS) and increased incidence of lung, bone and brain metastasis^{9–11}. Accordingly, Zou *et al.* found that KRAS mutations might be used as independent predictors of distant metastases in CRC¹². Moreover, KRAS mutations in CRC patients were significantly associated with the number of pulmonary metastasis and with the lung as first site of recurrence after pulmonary metastasectomy¹³. Besides, KRAS mutation has been reported to be a potential negative prognostic factor in patients with liver metastatic colorectal cancer in various treatment modalities^{14–16}.

Although the role of KRAS mutations in non-small cell lung cancer (NSCLC) is intensely investigated, there is limited and partly contradictory information on its prognostic role in lung cancer^{5,17–19}. A recent pooled analysis including 1362 patients from four EGFR-TKI randomized controlled trials failed to show a survival difference in the placebo arm between patients with KRAS-mutated and wild-type tumors¹⁹. Moreover, our group has recently demonstrated that KRAS mutation status per se is not prognostic in platinum based chemotherapy treated unresected stage III–IV LADC⁵. On the other hand, several other studies including large meta-analyses demonstrated that KRAS mutation has a negative prognostic impact especially in early stage LADC^{20–22}.

Beside its general prognostic role, the predictive value of KRAS mutational status in chemotherapy remains controversial¹⁷. Recently, a meta-analysis including 1677 advanced NSCLC patients revealed that patients with KRAS mutations had significantly lower ORR and potentially lower PFS after first-line chemotherapy²³. Furthermore, the presence of KRAS mutations had a mild negative impact on OS in advanced NSCLC patients treated with first-line chemotherapy in 52 Italian institutions²⁴. A retrospective analysis of 484 Asian advanced NSCLC patients showed only limited predictive role of KRAS mutation²⁵. Additionally, several other studies failed to show a predictive role of KRAS mutation for first-line chemotherapy efficacy^{26–28}.

Importantly, however, there is limited data available regarding the influence of KRAS mutation on the organ specificity of LADC metastases^{29–31}. Nevertheless, KRAS mutation might have different prognostic or predictive role depending on the site of dissemination. For this very reason, the aim of our study was to investigate the metastatic site-specific prognostic value of KRAS mutation in LADC patients.

Patients and Methods

Study Population. In our retrospective analysis, 532 consecutive Caucasian patients with cytologically or histologically verified stage IV LADC were included at the National Koranyi Institute of Pulmonology and at the Department of Pulmonology, Semmelweis University between January 2009 and March 2013. All patients were (re)staged using the 7th edition of the TNM classification³². Age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), smoking status, TNM stage and metastatic pattern was evaluated at the time of diagnosis. We differentiated single-organ and multiple-organ metastatic cases. Clinical follow-up was closed on the 1st of May, 2015. The study and all treatments were conducted in accordance with the current National Comprehensive Cancer Network guidelines, based on the ethical standards prescribed by the Helsinki Declaration of the World Medical Association and with the approval of the Scientific and Research Committee of the Hungarian Medical Research Council (52614–4/2013/EKU), which waived the need for individual informed consent for this retrospective study. Thirty-two patients with known EGFR mutations were excluded and the remaining 500 were analyzed within this study.

Molecular testing. Based on the knowledge that KRAS, EGFR and ALK (anaplastic lymphoma kinase) mutations are mutually exclusive (with rare reported exceptions)⁶, in Hungary KRAS testing is performed at first in all adenocarcinoma or adenosquamous cases to exclude KRAS-mutant cases from EGFR analysis as part of a diagnostic algorithm. This screening strategy results in a large number of cases with KRAS mutation data.

All mutational analyses were performed at the 2nd Department of Pathology and at the 1st Department of Pathology and Experimental Cancer Research, Semmelweis University as previously described³³. According to the contemporary National Comprehensive Cancer Network (NCCN) guideline³⁴, DNA isolation was performed from formalin fixed paraffin-embedded (FFPE) tissue blocks or cytological specimens of primary tumors or lymphatic or organ metastases (including pleural effusion).

KRAS mutations were identified by microcapillary-based restriction fragment length analysis as described⁵. Briefly, tumor-rich microscopic area on H&E staining had been determined by pathologists prior to macrodissection from FFPE tissue or cytological smears. DNA was extracted using the MasterPure™ DNA Purification Kit (Epicentre Biotechnologies, WI) according to the instructions of the manufacturer. The microfluid-based restriction fragment detection system characterized by 5% mutant tumor cell content sensitivity. Density ratio of the mutated band to the WT one was calculated and samples containing >5% of the non-WT band were considered mutation positive due to the sensitivity threshold. The base-pair substitution in the mutant samples were verified and determined by sequencing on the ABI 3130 Genetic Analyzer System (Life Technologies, Carlsbad, CA) with the BigDye® Terminator v1.1 Kit. EGFR mutation analysis was performed by Sanger Sequencing of the EGFR exon 18–21 as previously described⁴.

Statistical Methods. Categorical parameters (gender (female vs male), smoking status (never- vs ever (former and current)-smoker, ECOG PS (0 vs 1), and KRAS mutation status (mutant vs wild-type)) of the patients cohorts with different organ specific metastatic pattern (lung, bone, adrenal, brain, pleura, and liver) were statistically analyzed by Chi-square test. Age as a continuous variable was analyzed in the different single-organ metastatic groups by Student's t-test. Kaplan-Meier survival curves and two-sided log-rank tests were used for univariate survival analyses. The Cox proportional hazards model was used for univariate survival analyses to calculate the hazard ratios (HR) and corresponding 95% confidence intervals (CI). P values are always given as two-sided and were considered statistically significant below 0.05. Metric data is always shown as median or mean

Metastatic site	Total	Single-organ	Multiple-organ	Lung*	Bone*	Adrenal*	Brain*	Pleura*	Liver*	
Number of patients	500	362**	138	228	131	87	84	78	55	
Single-organ only				152	50	38	53	43	16	
Age (mean \pm SD)	61.9 \pm 9.4	62.3 \pm 9.3	60.8 \pm 9.7	62 \pm 8.9	60 \pm 10.7	63.1 \pm 6.8	59.7 \pm 9.2	66.8 \pm 10.4	64.4 \pm 9.1	
Gender	Male	245 (49%)	181 (50%)	64 (46%)	102 (45%)	74 (56%)	34 (39%)	36 (43%)	38 (49%)	26 (47%)
	Female	255 (51%)	181 (50%)	74 (54%)	126 (55%)	57 (44%)	53 (61%)	48 (57%)	40 (51%)	29 (53%)
ECOG PS	0–1	459 (94%)	335 (94%)	124 (92%)	218 (97%)	115 (91%)	75 (87%)	77 (93%)	71 (91%)	48 (91%)
	>1	32 (6%)	21 (6%)	11 (8%)	7 (3%)	11 (9%)	11 (13%)	6 (7%)	7 (9%)	5 (9%)
	Unknown	9	6	3	3	5	1	1	0	2
Smoking	Never	67 (15%)	52 (16%)	15 (12%)	29 (14%)	18 (16%)	7 (9%)	7 (9%)	20 (27%)	4 (8%)
	Former	141 (31%)	104 (31%)	37 (30%)	61 (29%)	32 (28%)	20 (25%)	25 (32%)	23 (32%)	20 (41%)
	Current	250 (54%)	179 (53%)	71 (58%)	117 (57%)	65 (58%)	52 (66%)	45 (58%)	30 (41%)	25 (51%)
	Unknown	42	27	15	21	16	8	7	5	6
KRAS	Wild-type	357 (71%)	263 (73%)	94 (68%)	148 (65%)	94 (72%)	58 (67%)	60 (71%)	65 (83%)	46 (84%)
	Mutant	143 (29%)	99 (27%)	44 (32%)	80 (35%)	37 (28%)	29 (33%)	24 (29%)	13 (17%)	9 (16%)
Median OS (months)	10.8	11.67	6.87	15.6	7.9***	14.4***	10.3***	8.8***	8.9***	

Table 1. Clinicopathological characteristics, overall survival (OS), KRAS mutational status and metastatic pattern in lung adenocarcinoma patients. *Values include both single- and multiple-organ cases except for OS. **In 10 cases, other than the listed types of metastasis was present (renal and subcutaneous). ***Only single-organ metastatic patients were included. Data shown in parentheses are column percentages; ECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival.




Figure 1. Metastatic site-specific variation of KRAS status. (A) Patients with multiple-organ metastases showed a non-significant increase in the percentage of KRAS mutant cases (vs single-organ spread, 32% v 27%). (B) In the organ-specific analysis, patients with brain, bone or adrenal gland metastases demonstrated similar KRAS mutation frequencies (29%, 28% and 33%, respectively). However, pulmonary metastatic cases demonstrated increased KRAS mutation frequency when compared to those with extrapulmonary metastases (35% and 26.5%; $p = 0.0125$). In contrast, pleural dissemination and liver metastasis associated with decreased KRAS mutation incidence (17% ($p < 0.001$) and 16% ($p = 0.0023$), respectively).

and corresponding range or, in case of OS, as median and corresponding 95% CI. All statistical analyses were performed using the PASW Statistics 18.0 package (Predictive Analytics Software, SPSS Inc., Chicago, IL, USA).

Results

Patient characteristics and metastatic pattern. Clinicopathological characteristics of patients with different metastatic pattern are shown in Table 1. We found 362 (72%) patients with single-organ metastatic disease and 138 (28%) cases with metastases affecting multiple organs (Table 1). The most frequent metastatic sites included lung (45.6%), bone (26.2%), adrenal gland (17.4%), brain (16.8%), pleura (15.6%), and liver (11%).

We did not find significant differences in age between the single-organ (62.3 \pm 9.3) vs multiple-organ (60.8 \pm 9.7) metastatic cohorts. Patients presented with only pleural spread (66.8 \pm 10.4) were significantly older than those with only lung (62 \pm 8.9), bone (60 \pm 10.7), adrenal (63.1 \pm 6.8) or brain (59.7 \pm 9.2) metastases




Figure 2. Kaplan-Meier curves for the OS of lung adenocarcinoma patients according to metastatic sites and KRAS mutation status. (A) Patients with multiple-organ metastases had significantly decreased median overall survival (OS) compared to those with single-organ metastasis (6.8 vs 11.6 months; HR, 0.62; 95% CI, 0.498 to 0.788; $p < 0.001$). (B) In the comparison of single-organ sites, patients presented with single-organ metastasis to the pleura demonstrated significantly decreased median OS when compared to those with lung (7.5 vs 15.6 months; HR, 0.460; 95% CI, 0.255 to 0.646; $p < 0.001$) or adrenal spread (7.5 vs 14.4 months; HR, 1.896; 95% CI, 1.154 to 3.114; $p = 0.011$). Furthermore, patients with brain metastasis showed significantly decreased OS when compared to patients presented with lung metastasis (median OS, 10.3 vs 15.6 months, respectively; HR, 1.5; 95% CI, 1.004 to 2.117; $p = 0.04$). We found no statistically significant information in any other organ specific comparison. KRAS mutation had no significant prognostic effect (C) in the full cohort of metastatic stage patients at diagnosis or according to (D) patients with single or multiple-organ spreads.

($p = 0.0024$, $p = 0.0008$, $p = 0.0132$, $p = 0.002$, respectively). Patients with brain involvement were significantly younger than those with lung metastasis ($p = 0.0094$).

The proportion of patients with ECOG PS 0–1 was similar in the different organ-specific metastatic subgroups. Of note, we found significantly higher numbers of never-smokers in the subgroup of patients with pleural metastases (27%) when compared to all other sites (12.2%, $p = 0.0018$).

Metastatic site-specific variation of KRAS status. KRAS mutation incidence was 28.6% in the full cohort. Patients with multiple-organ metastases showed a non-significant increase in the percentage of KRAS mutation (vs single-organ spread, 32% vs 27%, Table 1, Fig. 1A). Metastatic site-specific variation of KRAS status is shown in Fig. 1. Importantly, patients with brain (29%), bone (28%) or adrenal gland (33%) metastases demonstrated similar KRAS mutation frequencies (Table 1, Fig. 1B). However, pulmonary metastatic cases demonstrated increased KRAS mutation frequency when compared to those with all extrapulmonary metastases (35% and 26.5%, $p = 0.0125$, Fig. 1B). In contrast, pleural dissemination and liver metastasis were associated with decreased KRAS mutation incidence (vs all other metastatic sites; 17% ($p < 0.001$) and 16% ($p = 0.0023$), respectively).

Clinical Outcome. Patients with multiple-organ metastases had significantly decreased median overall survival (OS) compared to those with single-organ metastasis (6.8 vs 11.6 months, respectively; HR, 95% CI, 0.6262, 0.498 to 0.788, $p < 0.001$, Fig. 2A). Next, we compared the prognostic impact of single-organ metastatic sites (Fig. 2B). Patients with single-organ metastasis limited to the pleura demonstrated significantly decreased OS when compared to those with lung-only (median OS, 7.5 vs 15.6 months, HR, 0.460, 95% CI, 0.255 to 0.646; $p < 0.001$) or with adrenal-only spread (median OS, 7.5 vs 14.4 months, HR, 1.896, 95% CI, 1.154 to 3.114; $p = 0.011$). Furthermore, patients with brain metastasis showed significantly decreased OS when compared to patients presented with lung metastasis (median OS, 10.3 vs 15.6 months, respectively; HR, 1.5; 95% CI, 1.004 to 2.117; $p = 0.04$). There was no statistically significant difference in other organ specific comparison.




Figure 3. Kaplan-Meier curves for the OS of metastatic lung adenocarcinoma patients according to KRAS mutation status in patients with (A) lung, (B) bone, (C) adrenal, (D) brain, (E) pleura, and (F) liver spread. Both single- and multiple-organ metastatic cases were included in these analyses. We found a clinically relevant and also significant decrease in OS in patients presented with KRAS mutant bone metastasis (vs KRAS wild-type, median OS 3.7 v 9.7 months; HR, 0.49; 95% CI, 0.31 to 0.79; $p = 0.003$). Importantly, we found no statistically significant information in any other organ-specific comparison.

Next, we investigated the impact of KRAS mutation status on OS in the metastatic cohort (Fig. 2C) including the comparison of multiple- and single-organ metastatic subgroups (Fig. 2D). Importantly, we found no statistically significant information in these comparisons.

The impact of KRAS mutation status on OS of patients with different organ-specific metastases (including both multiple- and single-organ metastatic patients) is shown in Fig. 3. We observed a significant and clinically relevant decrease in OS in patients with KRAS-mutant tumors and with bone involvement (notably, this subcohort included bone metastatic cases with or without non-skeletal metastasis) (vs those with KRAS-WT tumors and bone involvement; median OS 3.7 v 9.7 months, respectively; HR, 0.49; 95% CI, 0.31 to 0.79; $p = 0.003$; Fig. 3B). Of note, no further statistically significant differences were observed in any other organ-specific comparison. Moreover, KRAS-mutant lung adenocarcinoma patients with dissemination limited to the skeletal system ($n = 13$) tended to have a shorter OS than those with KRAS-WT tumors (7.0 vs 10.2 months; $p = 0.21$, Supplemental Fig. 1).

Discussion

Despite of the extensive research, the prognostic and predictive power and thus the clinical utility of KRAS oncogenic mutations in lung adenocarcinoma has not yet been defined for over a decade^{5,17,35,36}. Surprisingly, there is very limited comprehensive data available regarding the influence of KRAS mutation on the organ specificity of lung adenocarcinoma metastases³⁷.

In line with other studies, we detected a significant decrease of median OS in patients with multiple-organ metastases³⁸. This observation further supports the proposal that NSCLC staging should take into account the number and site of metastases since tumors with a single metastasis in a single organ had significantly better prognosis than those with multiple metastases in one or several organs³⁹.

Comparing single-organ metastatic cases, we found that patients presented with metastasis to the pleura and brain showed significantly decreased OS when compared to patients exhibited lung metastasis. Earlier studies also showed that brain metastasis have an increased negative impact on survival^{40,41}.

The KRAS mutation rate in the presented cohort (28.6%) is in line with other studies^{17,42}. Patients with multiple-organ metastases showed a modest increase in the incidence of KRAS mutation. While there is no published data for lung adenocarcinoma, significantly increased frequency of KRAS mutation in patients with multiple organ metastases was found in a colorectal cancer study⁴³. With regards to metastatic sites, in line with previous findings of Doebele *et al.*³⁷, in our study patients with brain, bone or adrenal gland metastases demonstrated similar KRAS mutation frequencies. We detected 28% KRAS mutation frequency in the bone metastatic cohort which is similar to previous findings of Confavreux *et al.* and Bittner *et al.*^{44,45}. However, we found pleural dissemination and liver metastasis associated with decreased and intrapulmonary with increased KRAS mutation incidence of the primary. Importantly, in accordance with our study, in colorectal cancer, RAS mutation was associated with increased lung^{9,13} and decreased liver metastatic capacity^{43,46}. Nevertheless, further prospective studies are required to conclude if KRAS status can be used to risk stratify patients for the onset of pulmonary metastasis.

With regards to KRAS mutation status and the role of smoking in pulmonary metastasis, we found no association between metastatic pulmonary nodules and smoking. In previous studies, smoking was found not to be a significant risk factor in developing lung metastases in colorectal cancer either^{47–49}. In contrast, in esophageal and breast cancer, smoking was reported to be associated with pulmonary spread^{50,51}.

In line with other studies, we found a significant decrease of median OS in patients with multiple-organ metastases³⁸. Our finding further supports the proposal that the M stage should take into account the number of metastases and the number of metastatic sites as tumors with a single metastasis in a single organ had significantly better prognosis than those with multiple metastases in one or several organs³⁹.

To the best of our knowledge, this is the first study to directly compare the prognostic role of KRAS mutations in the distinct metastatic sites in lung adenocarcinoma. Importantly, we demonstrated a significant and also clinically relevant decrease in the OS of patients with KRAS-mutant lung adenocarcinoma and bone metastasis. The differences between the clinicopathological characteristics of KRAS-WT and KRAS-mutant bone-metastatic patients cannot explain the observed decrease in OS. Of note, we found higher frequency of multiple-organ metastases in KRAS-WT patients presenting with bone metastases when compared to KRAS-mutant cases (84% v46%, $p < 0.0001$).

Our study has several limitations, in part due to its retrospective nature. Although we excluded EGFR mutants from our study, the KRAS-WT cohort was not analyzed for additional oncogenic driver mutations. In addition, reflecting the routine clinical practice the majority of patients are evaluated by clinical and not pathological TNM staging. Accordingly, we are not able to exclude the presence of asymptomatic disease or micro metastases. It is important to mention that in the case of the relatively less frequent metastatic site with the lowest KRAS mutation incidence, namely in the liver metastasis subgroup, we do not have sufficient statistical power to determine the impact of KRAS mutation on overall survival.

Despite enormous attempts the prognostic value and the clinical utility of the most frequently occurring oncogene have not been established in advanced stage lung adenocarcinoma for over a decade. Consequently, guidelines lack information on the clinical benefit of KRAS mutation testing in NSCLC. Therefore, and more importantly, our study addresses an important issue and highlights the possible prognostic importance and potential clinical relevance of KRAS mutation. In addition, our study is the first that showed metastatic site-specific variation of the prognostic value of KRAS status in lung adenocarcinoma. We suggest the KRAS mutation status may have important implications for diagnostic strategies and treatment decisions. Our results indicate that KRAS mutation status has a strong prognostic value in bone metastatic lung adenocarcinoma patients. Nevertheless, additional studies are needed to evaluate the ability of KRAS mutation analysis to risk stratify patients with bone metastasis. Future studies are also required to investigate whether KRAS status might even predict response to various treatment options for bone metastatic patients.

References

1. Bos, J. L. Ras Oncogenes in Human Cancer - a Review. *Cancer Res* **49**, 4682–4689 (1989).
2. Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. *Cancer Res* **72**, 2457–2467 (2012).
3. Aviel-Ronen, S., Blackhall, F. H., Shepherd, F. A. & Tsao, M. S. K-ras mutations in non-small-cell lung carcinoma: A review. *Clin Lung Cancer* **8**, 30–38 (2006).
4. Lohinai, Z. *et al.* Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer* **10**, 738–746 (2015).
5. Cserepes, M. *et al.* Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. *European journal of cancer* **50**, 1819–1828 (2014).
6. Lindeman, N. I. *et al.* Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Archives of pathology & laboratory medicine* **137**, 828–860 (2013).
7. Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A. & Eckhardt, S. G. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* **27**, 1130–1136 (2009).
8. Sorich, M. J. *et al.* Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. *Ann Oncol* **26**, 13–21 (2015).
9. Yaeger, R. *et al.* RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. *Cancer* **121**, 1195–1203 (2015).

10. Petrelli, F. *et al.* Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients. *Med Oncol* **32**, 456–466 (2015).
11. Mise, Y. *et al.* RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. *Ann Surg Oncol* **22**, 834–842 (2015).
12. Zhu, K. *et al.* Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer. *Med Oncol* **31**, 16–23 (2014).
13. Schweiger, T. *et al.* EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. *Ann Surg Oncol* **21**, 946–954 (2014).
14. Stremitzer, S. *et al.* KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. *Br J Surg* **99**, 1575–1582 (2012).
15. Nash, G. M. *et al.* KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. *Ann Surg Oncol* **17**, 572–578 (2010).
16. Passiglia, F. *et al.* Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. *Crit Rev Oncol Hematol* **99**, 150–157 (2016).
17. Martin, P., Leighl, N. B., Tsao, M. S. & Shepherd, F. A. KRAS Mutations as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer* **8**, 530–542 (2013).
18. Renaud, S. *et al.* Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases. *British journal of cancer* **113**, 1206–1215 (2015).
19. Zer, A. *et al.* Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. *Journal of thoracic oncology* **11**, 312–323 (2016).
20. Mascaux, C. *et al.* The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. *British journal of cancer* **92**, 131–139 (2005).
21. Slebos, R. J. *et al.* K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. *The New England journal of medicine* **323**, 561–565 (1990).
22. Meng, D. *et al.* Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. *Lung Cancer* **81**, 1–10 (2013).
23. Zhang, Y. *et al.* The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis. *Med Oncol* **32**, 61–72 (2015).
24. Marabese, M. *et al.* KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. *Oncotarget* **6**, 34014–34022 (2015).
25. Sun, J. M., Hwang, D. W., Ahn, J. S., Ahn, M. J. & Park, K. Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. *PLoS One* **8**, e64816, doi: 10.1371/journal.pone.0064816 (2013).
26. Dong, X. *et al.* Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status. *Clin Lung Cancer* **14**, 680–687 (2013).
27. Mellema, W. W. *et al.* KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer* **8**, 1190–1195 (2013).
28. O'Byrne, K. J. *et al.* Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. *The Lancet. Oncology* **12**, 795–805 (2011).
29. Yu, H. A. *et al.* Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. *Cancer* **121**, 2078–2082 (2015).
30. Renaud, S. *et al.* Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer. *Future Oncol* **12**, 59–70 (2016).
31. Zhao, N. *et al.* Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. *Lung Cancer* **86**, 255–261 (2014).
32. Goldstraw, P. *et al.* The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer* **2**, 706–714 (2007).
33. Szabo, B. *et al.* Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. *Oral oncology* **47**, 487–496 (2011).
34. National Comprehensive Cancer Network. *NCCN Guidelines Non-small cell lung cancer. Version 3.2017*. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp (2016).
35. Mascaux, C. *et al.* The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. *British journal of cancer* **92**, 131–139 (2005).
36. Levy, B. P. *et al.* Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. *The oncologist* **20**, 1175–1181 (2015).
37. Doebele, R. C. *et al.* Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. *Cancer* **118**, 4502–4511 (2012).
38. He, Y. Y. *et al.* Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer. *Clin Lung Cancer* **15**, 441–447 (2014).
39. Eberhardt, W. E. *et al.* The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *Journal of thoracic oncology* **10**, 1515–1522 (2015).
40. Langer, C. J. & Mehta, M. P. Current management of brain metastases, with a focus on systemic options. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* **23**, 6207–6219 (2005).
41. Kepka, L., Cieslak, E., Bujko, K., Fijuth, J. & Wierzchowski, M. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-classes analysis. *Acta oncologica* **44**, 389–398 (2005).
42. Eberhard, D. A. *et al.* Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *Journal of Clinical Oncology* **23**, 5900–5909 (2005).
43. Modest, D. P. *et al.* Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. *Anti-cancer drugs* **22**, 913–918 (2011).
44. Confavreux, C. B. *et al.* Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). *BoneKey reports* **3**, 580, doi: 10.1038/bonekey.2014.75 (2014).
45. Bittner, N. *et al.* Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma—The Results of Three Year Retrospective Analysis. *Pathology oncology research: POR* **21**, 1217–1221 (2015).
46. Tsunoda, A. *et al.* Association of K-ras mutations with liver metastases from colorectal carcinoma. *Anticancer research* **24**, 2471–2476 (2004).
47. Watanabe, K. *et al.* Incidence and predictive factors for pulmonary metastases after curative resection of colon cancer. *Ann Surg Oncol* **20**, 1374–1380 (2013).

48. Watanabe, K. *et al.* Predictive factors for pulmonary metastases after curative resection of rectal cancer without preoperative chemoradiotherapy. *Diseases of the colon and rectum* **54**, 989–998 (2011).
49. Varol, Y. *et al.* The frequency and significance of radiologically detected indeterminate pulmonary nodules in patients with colorectal cancer. *Medical principles and practice: international journal of the Kuwait University, Health Science Centre* **21**, 457–461 (2012).
50. Murin, S. & Inciardi, J. Cigarette smoking and the risk of pulmonary metastasis from breast cancer. *Chest* **119**, 1635–1640 (2001).
51. Abrams, J. A., Lee, P. C., Port, J. L., Altorki, N. K. & Neugut, A. I. Cigarette smoking and risk of lung metastasis from esophageal cancer. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* **17**, 2707–2713 (2008).

Acknowledgements

We acknowledge the support of the IASLC International Mentorship Program 2015 (ZL). ZL was a recipient of the Hungarian Pulmonology Research Fellowship and the ESMO Translational Research Fellowship. IK is the recipient of the Janos Bolyai Fellowship of the Hungarian Academy of Sciences. The authors were supported by AIK 12-1-2013-0041 (GO, FRV, BD), the Hungarian National Research, Development and Innovation Office (K109626, K108465 and SNN114490: BD; MOB80325: BH and PD109580: IK), the Semmelweis University Start-Up grant (40148-11658: BD) and the Vienna Fund for Innovative Interdisciplinary Cancer Research (BD). JT acknowledges funding from The National Research, Development and Innovation Office of Hungary (NKFIH/OTKA-K116151, KTIA-NAP-13-2014-0021 and NVKP_16-1-2016-0020).

Author Contributions

Z.L., T.K., J.M., G.O., E.R., J.T., K.F., I.L.K., I.S.K., C.A., F.R., W.K., B.D. and B.H. contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript. B.D. and B.H. confirm that the study objectives and procedures are honestly disclosed. Moreover, they have reviewed study execution data and confirm that procedures were followed to an extent that convinces all authors that the results are valid and generalizable to a population similar to that enrolled in this study. All authors have provided final approval of the version to be published and have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Lohinai, Z. *et al.* KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS-mutation and bone metastasis. *Sci. Rep.* **7**, 39721; doi: 10.1038/srep39721 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017